ARQT
Price
$20.11
Change
+$0.03 (+0.15%)
Updated
Oct 24 closing price
Capitalization
2.41B
2 days until earnings call
Intraday Buy/Sell Signals
DMAC
Price
$6.88
Change
+$0.12 (+1.78%)
Updated
Oct 24 closing price
Capitalization
355.62M
10 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ARQT vs DMAC

Header iconARQT vs DMAC Comparison
Open Charts ARQT vs DMACBanner chart's image
Arcutis Biotherapeutics
Price$20.11
Change+$0.03 (+0.15%)
Volume$1.19M
Capitalization2.41B
DiaMedica Therapeutics
Price$6.88
Change+$0.12 (+1.78%)
Volume$309.49K
Capitalization355.62M
ARQT vs DMAC Comparison Chart in %
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARQT vs. DMAC commentary
Oct 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and DMAC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 26, 2025
Stock price -- (ARQT: $20.11 vs. DMAC: $6.88)
Brand notoriety: ARQT and DMAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 69% vs. DMAC: 84%
Market capitalization -- ARQT: $2.41B vs. DMAC: $355.62M
ARQT [@Biotechnology] is valued at $2.41B. DMAC’s [@Biotechnology] market capitalization is $355.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARQT and DMAC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 4 TA indicator(s) are bullish while DMAC’s TA Score has 4 bullish TA indicator(s).

  • ARQT’s TA Score: 4 bullish, 4 bearish.
  • DMAC’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than ARQT.

Price Growth

ARQT (@Biotechnology) experienced а -3.69% price change this week, while DMAC (@Biotechnology) price change was +4.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.97%. For the same industry, the average monthly price growth was +11.13%, and the average quarterly price growth was +63.98%.

Reported Earning Dates

ARQT is expected to report earnings on Oct 28, 2025.

DMAC is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARQT($2.41B) has a higher market cap than DMAC($356M). ARQT YTD gains are higher at: 44.365 vs. DMAC (26.704). DMAC has higher annual earnings (EBITDA): -31.42M vs. ARQT (-68.35M). ARQT has more cash in the bank: 191M vs. DMAC (30M). DMAC has less debt than ARQT: DMAC (292K) vs ARQT (110M). ARQT has higher revenues than DMAC: ARQT (263M) vs DMAC (0).
ARQTDMACARQT / DMAC
Capitalization2.41B356M677%
EBITDA-68.35M-31.42M218%
Gain YTD44.36526.704166%
P/E RatioN/AN/A-
Revenue263M0-
Total Cash191M30M637%
Total Debt110M292K37,671%
FUNDAMENTALS RATINGS
DMAC: Fundamental Ratings
DMAC
OUTLOOK RATING
1..100
24
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
76
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARQTDMAC
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 7 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 10 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
80%
Aroon
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ARQT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AOFIX22.300.37
+1.69%
Alger Small Cap Focus I
SEEKX40.020.32
+0.81%
Steward Values Enhanced Lg Cap A
CIVHX20.460.04
+0.20%
American Funds International Vntg 529-F3
ARIDX6.13N/A
N/A
AMG River Road Dividend All Cap Value I
MCVRX31.38-0.03
-0.10%
MFS Mid Cap Value R2

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with ROIV. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
+0.15%
ROIV - ARQT
47%
Loosely correlated
+0.55%
WVE - ARQT
47%
Loosely correlated
+1.13%
IDYA - ARQT
47%
Loosely correlated
+2.67%
NRIX - ARQT
46%
Loosely correlated
+6.63%
KRYS - ARQT
46%
Loosely correlated
-0.17%
More